Company profile

Lantern Pharma Inc.

LTRN (EDGAR registrant "Lantern Pharma Inc." with listed ticker LTRN [resolved 2026-08-05 by resolve-null-is-public; source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001763950])

Share price · LTRN

$2.52-0.48 (-16.00%) 3M

close as of 2026-08-18 · 24h delayed · vol 69K

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento

Assets

(2 total)

2Total Assets

0Approved

1Phase 3 / Filed

1Phase 1–2 / Early

1Diseases

Showing 2 of 2 assets

		Target & Modality
LP-300	Phase 3	EGFR / ALK / MET / ROS1 (via extracellular disulfide-bond disruption)Small molecule	Non-Small Cell Lung Cancer
LP-184	Phase 2	PTGR1 (Prostaglandin Reductase 1, bioactivating enzyme)Small molecule	Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.